Turn the Future Dice with Site Less Clinical Trials
In common with many areas in pharma, drug development is in a state of constant change. The emergence of disruptive technologies combined with the powerful push towards patient-centricity are forcing companies to shake off idleness and think about radical new models.
One such model would have been unthinkable a decade ago but now, interest in clinical trials taking place outside the clinic is growing exponentially. with an emphasis on remote observing and patient recruitment, 'site less' or direct-to-patient clinical trials have the potential to impact the most perennial of problems - patient recruitment and retention. In addition to the sheer convenience for patients, site less trials tear down geographic barriers, opening up trials to more extensive - and potentially more diverse and representative - patient population.